Adaptive Biotechnologies Corporation (ADPT)
NASDAQ · Healthcare
Adaptive Biotechnologies Corporation EBITDA 2017–2025
Adaptive Biotechnologies Corporation annual/quarterly ebitda history and growth rate from 2022 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Adaptive Biotechnologies Corporation ebitda for the quarter ending March 31, 2026 was -15.8 M, a 37.51% decrease year-over-year.
- Adaptive Biotechnologies Corporation ebitda for the twelve months ending March 31, 2026 was -47.8 M, a 70.09% decrease year-over-year.
- Adaptive Biotechnologies Corporation annual ebitda for 2025 was -41.1 M, a 71.66% decrease from 2024.
- Adaptive Biotechnologies Corporation annual ebitda for 2024 was -145.1 M, a 30.05% decrease from 2023.
- Adaptive Biotechnologies Corporation annual ebitda for 2023 was -207.4 M, a 15.71% increase from 2022.
- Adaptive Biotechnologies Corporation annual ebitda for 2022 was -179.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Adaptive Biotechnologies Corporation EBITDA — FAQ
Adaptive Biotechnologies Corporation (ADPT) ebitda over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ADPT's ebitda history?
The chart and table above show Adaptive Biotechnologies Corporation's ebitda by year and by quarter, including the growth rate.